Table 2. Prognostic factors for OS for ICC patients after surgery.
| Factor | Univariate analysis | Multivariate analysisc | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age ≥60 years | 0.811 (0.513–1.282) | 0.369 | – | – | |
| Female | 0.689 (0.439–1.084) | 0.107 | – | – | |
| BMI ≥24 kg/m2 | 1.441 (0.908–2.286) | 0.121 | – | – | |
| Comorbidity | 0.781 (0.494–1.235) | 0.291 | – | – | |
| ASA score 3–4 | 1.227 (0.590–2.552) | 0.584 | – | – | |
| Preoperative therapy | 0.611 (0.193–1.941) | 0.404 | – | – | |
| Adjuvant therapy | 0.659 (0.406–1.070) | 0.092 | – | – | |
| Cirrhosis | 0.961 (0.605–1.527) | 0.866 | – | – | |
| HBsAg (+) | 0.729 (0.408–1.301) | 0.285 | – | – | |
| Microvascular invasion | 2.050 (1.014–4.146) | 0.046 | 3.232 (1.281–8.156) | 0.013 | |
| T3–T4 stage | 2.360 (1.438–3.872) | 0.001 | 3.426 (1.385–8.472) | 0.008 | |
| Complication | 1.013 (0.642–1.599) | 0.954 | – | – | |
| Lymph node metastasis | <0.001 | – | – | ||
| Undissected lymph node | Reference | ||||
| Negative lymph node | 0.717 (0.413–1.246) | 0.238 | |||
| Positive lymph node | 2.592 (1.475–4.556) | 0.001 | |||
| Tumor size ≥5 cm | 1.491 (0.950–2.339) | 0.082 | – | – | |
| Multiple metastases | 1.633 (0.958–2.785) | 0.072 | – | – | |
| Tumor location | 0.796 | – | – | ||
| Left liver lobe | Reference | ||||
| Right liver lobe | 1.118 (0.703–1.778) | 0.638 | |||
| Other | 1.311 (0.545–3.154) | 0.546 | |||
| Operation time ≥230 mina | 1.738 (1.110–2.722) | 0.016 | – | – | |
| Blood loss ≥300 mLa | 1.710 (1.069–2.736) | 0.025 | – | – | |
| Tumor location | – | – | |||
| Central tumor | Reference | – | |||
| Edged tumor | 1.638 (1.042–2.573) | 0.032 | |||
| Poorly differentiation | 1.542 (0.961–2.474) | 0.073 | – | – | |
| Hemi-hepatectomy | 1.109 (0.698–1.761) | 0.661 | – | – | |
| TBIL ≥21 μmol/L | 0.878 (0.422–1.824) | 0.726 | – | – | |
| AST ≥40 U/L | 1.647 (0.848–3.200) | 0.141 | – | – | |
| ALT ≥50 U/L | 1.604 (0.825–3.120) | 0.164 | – | – | |
| GGT ≥60 U/L | 1.390 (0.889–2.174) | 0.148 | – | – | |
| Preoperative CA19-9 ≥871.65 U/mLa | 4.024 (2.331–6.950) | <0.001 | 2.639 (0.983–7.088) | 0.054 | |
| Preoperative D-dimer ≥0.365 mg/La | 2.632 (1.650–4.198) | <0.001 | 5.009 (1.732–14.486) | 0.003 | |
| Preoperative CEA ≥2.53 ng/mLa | 2.217 (1.382–3.557) | 0.001 | – | – | |
| Preoperative FIB ≥3.67 g/La | 1.857 (1.141–3.022) | 0.013 | – | – | |
| The prognostic value on CPDC scoreb | |||||
| CPDC =0 | Reference | <0.001 | Reference | <0.001 | |
| CPDC =1 | 2.924 (1.559–5.482) | 0.001 | 4.969 (1.711–14.436) | 0.003 | |
| CPDC =2 | 6.579 (3.286–13.171) | <0.001 | 13.225 (4.124–42.414) | <0.001 | |
a, ROC curves were constructed to estimate the optimal cutoff value; b, because the CPDC score was based on the D-dimer levels and CA19-9 levels, the multivariate analysis of prognostic value of CPDC score included factors with a P<0.1 in univariate analysis exclude of the D-dimer levels and CA19-9 levels; c, clinicopathological factors with a P<0.1 in univariate analysis were included in multivariate analysis. Multivariable analysis was performed using Cox regression models. Forward: LR was used in multivariate analysis. OS, overall survival; ICC, intrahepatic cholangiocarcinoma; HR, hazard ratio; CI, confidence interval; BMI, body mass index; ASA, American Society of Anesthesiologists; HBsAg, serum hepatitis B surface antigen; TBIL, total bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyl transferase; CEA, carcinoembryonic antigen; FIB, fibrinogen; CPDC, combination of preoperative D-dimer and CA19-9; ROC, receiver operating characteristic curve; LR, likelihood ratio.